Ultragenyx製藥 RARE 深 滬
已收盤 09-05 16:00:00 美东时间
31.82
+0.540
+1.73%
華盛通- 最 高32.26
- 今 開31.73
- 成交量 132.54万股
- 最 低 31.28
- 昨 收 31.28
- 總市值 30.67亿
- 52周最高 60.37
- 市盈率 靜 --
- 換手率 1.38%
- 52周最低 25.81
- 委 比 43.20%
- 總股本 9637.16万
- 歷史最高 179.647
- 量 比 0.89
- 振 幅 3.13%
- 歷史最低 25.81
- 每 手 1
- 風險率 8.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Assessing Ultragenyx Pharmaceutical: Insights From 8 Financial Analysts
In the preceding three months, 8 analysts have released ratings for Ultragenyx ...
09-05 22:01
Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $105 Price Target
Cantor Fitzgerald analyst Kristen Kluska reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and maintains $105 price target.
09-05 21:44
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals
FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact.
09-05 02:50
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
09-03 01:35
Ultragenyx to Participate at Investor Conferences in September
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced its participation in three upcoming investor conferences in September 2025. Eric Crombez, M.D., Chief Medical Officer, and Howard Horn, Chief Financial Officer, will attend the Cantor Global Healthcare Conference on September 4 in New York. Eric Crombez will also participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9 and the Bank of America Global Healthcar...
08-29 20:30
Mereo BioPharma signs licensing deal with privately held āshibio
Mereo BioPharma (NASDAQ:MREO) signed an exclusive licensing deal with privately held biotech āshibio, for the antibody therapy vantictumab, intended to treat autosomal dominant osteopetrosis type 2. A...
08-19 21:43
Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
Ultragenyx Pharmaceutical Inc. announced the initiation of a rolling submission of a Biologics License Application (BLA) to the FDA for DTX401 AAV gene therapy, intended to treat Glycogen Storage Disease Type Ia (GSDIa). The company has already submitted non-clinical and clinical modules and plans to complete the full BLA, including the chemistry, manufacturing, and controls (CMC) module, by the fourth quarter of 2025. The BLA includes 96-week da...
08-18 12:00
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
What to Expect from Kymera Therapeutics's Earnings
Kymera Therapeutics (NASDAQ:KYMR) is gearing up to announce its quarterly earni...
08-08 23:01
8 Analysts Assess Ultragenyx Pharmaceutical: What You Need To Know
Across the recent three months, 8 analysts have shared their insights on Ultrag...
08-07 06:01
